GlassScriptPhysician profile
James G Marble
NPI 1629631700
$1,490.93
in general payments reported to CMS, 2019-2025
25 companies · $561 in 2025
The $561 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $59.78 · 2023: $446 · 2024: $423 · 2025: $561.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,315 · Education: $116.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,315.15 |
| Education | $116.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $326.76 | 2023-2025 | |
| Novo Nordisk INC | $205.54 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $104.12 | 2024-2025 | Evenity, Prolia, Repatha |
| Myriad Women'S Health, INC. | $83.37 | 2023 | |
| Merck Sharp & Dohme LLC | $75.48 | 2023-2025 | Gardasil 9, Capvaxive, Enflonsia |
| Astellas Pharma US INC | $64.52 | 2022-2023 | Veozah |
| Grifols USA, LLC | $61.00 | 2022-2023 | Prolastin-C Liquid |
| Neurocrine Biosciences, INC. | $58.55 | 2024-2025 | Ingrezza |
| Vanda Pharmaceuticals INC. | $51.33 | 2024-2025 | Fanapt |
| Glaxosmithkline, LLC. | $46.71 | 2023-2024 | Trelegy Ellipta, Arexvy, Bexsero |
| Exact Sciences Corporation | $44.40 | 2025 | Cologuard Collection Kit |
| Mylan Specialty L.P. | $43.73 | 2024 | Yupelri |
| Sumitomo Pharma America, INC. | $39.15 | 2024-2025 | Gemtesa |
| Bayer Healthcare Pharmaceuticals INC. | $32.82 | 2023-2025 | |
| Tandem Diabetes Care, INC. | $32.22 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $30.14 | 2025 | Zepbound, Mounjaro |
| Teva Pharmaceuticals USA, INC. | $30.13 | 2023-2025 | Austedo Xr, Austedo |
| Pfizer INC. | $27.55 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $24.56 | 2023 | Trintellix |
| Boston Scientific Corporation | $23.41 | 2025 | Watchman Access System |
| Shield Therapeutics INC | $20.75 | 2024 | |
| Genentech USA, INC. | $17.44 | 2025 | Ocrevus Zunovo |
| Viatris Specialty LLC | $17.15 | 2025 | Yupelri |
| Janssen Pharmaceuticals, INC | $15.77 | 2023 | Xarelto |
| Therapeuticsmd, INC. | $14.33 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Marble listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.